标题
Acute myeloid leukaemia
作者
关键词
-
出版物
LANCET
Volume 401, Issue 10393, Pages 2073-2086
出版商
Elsevier BV
发表日期
2023-04-15
DOI
10.1016/s0140-6736(23)00108-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Time to blur the blast boundaries
- (2022) Courtney D. DiNardo et al. CANCER
- Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
- (2022) Nicolas Duployez et al. BLOOD
- The longitudinal dynamics and natural history of clonal haematopoiesis
- (2022) Margarete A. Fabre et al. NATURE
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
- (2022) Pau Montesinos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission
- (2022) Madlen Jentzsch et al. Blood Advances
- Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
- (2022) Andrew H Matthews et al. Blood Advances
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data
- (2022) Daniel A. Arber et al. BLOOD
- Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.
- (2022) Stéphane De Botton et al. JOURNAL OF CLINICAL ONCOLOGY
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- (2022) Joseph D. Khoury et al. LEUKEMIA
- Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML
- (2021) Martin Wermke et al. BLOOD
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
- (2021) Laura Katharina Schmalbrock et al. BLOOD
- De novo acute myeloid leukemia: A population‐ based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
- (2021) Koji Sasaki et al. CANCER
- Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal
- (2021) Elihu H Estey et al. BLOOD
- Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission
- (2021) Takaaki Konuma et al. BONE MARROW TRANSPLANTATION
- Germline predisposition to hematopoietic malignancies
- (2021) Simone Feurstein et al. HUMAN MOLECULAR GENETICS
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
- (2021) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute promyelocytic leukemia current treatment algorithms
- (2021) Musa Yilmaz et al. Blood Cancer Journal
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
- (2021) Jeffrey E Lancet et al. Lancet Haematology
- Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
- (2021) Sijian Yu et al. JAMA Network Open
- Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
- (2021) Inge van der Werf et al. Blood Advances
- Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy
- (2021) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
- (2021) Justin Grenet et al. BLOOD
- 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
- (2021) Michael Heuser et al. BLOOD
- Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges
- (2021) Kiran Tawana et al. BRITISH JOURNAL OF HAEMATOLOGY
- Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
- (2021) Christopher J. Gibson et al. JOURNAL OF CLINICAL ONCOLOGY
- Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2021) Kelly J. Norsworthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
- (2021) Ing S. Tiong et al. Blood Advances
- Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
- (2021) Keith W. Pratz et al. JOURNAL OF CLINICAL ONCOLOGY
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
- (2020) David A Sallman et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Molecular MRD status and outcome after transplantation in NPM1-mutated AML
- (2020) Richard Dillon et al. BLOOD
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
- (2020) Christoph Röllig et al. BLOOD
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
- (2020) Claude Gardin et al. Blood Advances
- Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
- (2020) Geoffrey L Uy et al. BLOOD
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis
- (2020) Kelly L. Bolton et al. NATURE GENETICS
- Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
- (2020) Amy Burd et al. NATURE MEDICINE
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia
- (2020) Nicholas J. Short et al. JAMA Oncology
- Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
- (2020) Charles Craddock et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
- (2020) Nicholas J. Short et al. Blood Advances
- Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved
- (2020) Rory M. Shallis et al. BLOOD REVIEWS
- Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
- (2019) Gerwin Huls et al. BLOOD
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
- (2019) Miguel A. Sanz et al. BLOOD
- Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
- (2019) Gunnar Juliusson et al. BLOOD
- Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
- (2019) Rong He et al. MODERN PATHOLOGY
- How I treat acute myeloid leukemia in the era of new drugs
- (2019) Courtney D. DiNardo et al. BLOOD
- Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
- (2019) Megan Othus et al. BONE MARROW TRANSPLANTATION
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal hematopoiesis in human aging and disease
- (2019) Siddhartha Jaiswal et al. SCIENCE
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
- (2019) Christopher S. Hourigan et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states
- (2019) Lukasz P Gondek et al. Lancet Haematology
- Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
- (2018) Chezi Ganzel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays
- (2018) Catherine C. Coombs et al. CLINICAL CANCER RESEARCH
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
- (2018) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Managing Clonal Hematopoiesis in Patients With Solid Tumors
- (2018) Kelly L. Bolton et al. JOURNAL OF CLINICAL ONCOLOGY
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
- (2018) Kyle J Foreman et al. LANCET
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC)
- (2016) Courtney D. DiNardo et al. Clinical Lymphoma Myeloma & Leukemia
- Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
- (2016) Chezi Ganzel et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
- (2015) R J Molenaar et al. LEUKEMIA
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
- (2014) R. C. Lindsley et al. BLOOD
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
- (2014) R B Walter et al. LEUKEMIA
- Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia
- (2014) Uri Rozovski et al. LEUKEMIA & LYMPHOMA
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
- (2013) F Ferrara et al. LEUKEMIA
- Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML
- (2013) K Takahashi et al. LEUKEMIA
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- (2013) Francesco Lo-Coco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now